Project Grant R21CA301519
Award Date 4/1/26
Completion Date 3/31/28
Dollars Obligated $435K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Denver, CO 80206, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute awarded $1,034,176 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) on August 18, 2025, for a project extending through July 31, 2032. The research focuses on understanding and targeting aberrant RNA splicing in leukemia, building on the principal investigator's 13-year track record of discovering genetic alterations in hematopoietic malignancies. The project aims to...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $495,715 to the Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) on August 5, 2025, with a completion date of July 31, 2030. This award funds fundamental research to decipher the pathogenesis and therapeutic vulnerabilities in germline RUNX1-mutated acute myeloid leukemia (AML). The research focuses on understanding how germline RUNX1 mutations...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $584,510 to the University of Colorado-Denver on September 12, 2025, under the Cancer Biology Research program (CFDA 93.396) to support the development and implementation of advanced spatial transcriptomics and proteomics technologies for studying tumor microenvironments. Through the Human Immune Monitoring Shared Resource (HIMSR) at the University of Colorado Cancer Center, this funding supports a...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $223,176 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to Duke University on September 10, 2025, with a completion date of April 30, 2028. This F32 postdoctoral fellowship award supports research investigating the role of SMARCAL1 (an annealing helicase) depletion in enhancing immunogenicity within Alternative Lengthening of Telomeres (ALT)-positive high-grade gliomas. The research addresses a...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $418,176 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) to advance programmable nucleic acid cytometry technology for isolating and analyzing rare cell populations from tumors and tissues. The three-year project, initiated September 1, 2025 and concluding August 31, 2028, focuses on continued development and validation of Programmable Enrichment via RNA...
- Federal Grant Award Summary The National Cancer Institute awarded $138,846 to the University Health Network under the Cancer Detection and Diagnosis Research program (CFDA 93.394) for a two-year Project Grant commencing August 1, 2025 and concluding July 31, 2027. The award supports the development of laboratory-generated "wild-like" mouse models designed to enhance the translational relevance of preclinical cancer and immunotherapy research. The primary deliverable involves adapting...
- Federal Project Grant Summary The National Cancer Institute (NCI) awarded $770,666 to the University of Colorado (The Regents of the University of Colorado) under the Cancer Biology Research program (CFDA 93.396) on March 19, 2026, with completion targeted for February 28, 2028. The project, "Splicing-Mediated Dysregulation of Interferon Signaling in Cancer," will investigate how transposon-derived exonized variants of the IFNAR2 gene contribute to cancer treatment resistance. The...
- Federal Grant Award Summary The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research a $452,540 Project Grant under the Cancer Biology Research program (CFDA 93.396) for the period of May 1, 2026 through April 30, 2028. This award supports fundamental research investigating the innate and adaptive determinants of cytokine release syndrome (CRS) following chimeric antigen receptor (CAR) T-cell therapy. The research aims to elucidate the molecular mechanisms underlying...
- Federal Project Grant Award Summary The National Cancer Institute's Cancer Biology Research program (CFDA 93.396) awarded Columbia University's Health Sciences Division a $501,422 Project Grant effective May 1, 2026, through April 30, 2031, to advance novel synthetic lethal (SL) therapeutic targets in cancer. The research focuses on validating the PELOTA (PELO) and HBS1-like translational GTPase (HBS1L) ribosome rescue complex as a synthetic lethal target for two distinct cancer subtypes:...
- Federal Grant Award Summary St. Jude Children's Research Hospital Inc. received a $1,049,120 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective May 21, 2025, with completion scheduled for April 30, 2030. The award supports fundamental research into the structural biology and neomorphic functions of SPOP (Speckle-Type POZ Protein), a substrate receptor component of the Cullin3-RING ubiquitin ligase complex. The...